MedTrace Logo

Evaluation of Metabolic Profile of OC000459

NCT02341521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-05-25

No results posted yet for this study

Summary

An open label study in 9 male and 9 female healthy subjects to determine the pharmacokinetics of parent compound and metabolite after eight days of dosing.

Conditions

Interventions

DRUG

OC000459

Taken orally for 8 days

Sponsors & Collaborators

  • Simbec Research

    collaborator INDUSTRY

  • Atopix Therapeutics, Ltd.

    lead INDUSTRY

Principal Investigators

  • Salvatore Febbraro, MD · Simbec Research

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341521 on ClinicalTrials.gov